Literature DB >> 6389723

Neutralization of interferon by antibody: appraisals of methods of determining and expressing the neutralization titer.

Y Kawade, Y Watanabe.   

Abstract

Basic problems in the quantitation of interferon (IFN) neutralization by antibody were considered. Commonly used experimental methods were examined, and the "constant antibody method" (the IFN dose-response [e.g., cytopathic effect] curve is depicted in the presence of fixed concentrations of antibody) was found to be the most convenient and informative; the "constant IFN method" which is widely used is in principle equivalent, but not suitable for tests of IFN of mixed antigenic types and for monoclonal antibodies. As previously proposed (J. IFN Res. 1, 61, 1980), the antibody titer is defined not by neutralization of a fixed absolute amount of IFN (such as 10 international units), but by the IFN titer reduction factor, namely as the reciprocal of antibody dilution that neutralizes 10 experimental units (EU)/ml of IFN to 1 EU/ml. This definition was found satisfactory for many antibodies to human and mouse IFNs, in that the value for given antibody did not change with changes in IFN sensitivity of the assay system, whereas the titer based on the absolute amount of IFN neutralized did. In other words, a given antibody will neutralize a larger amount of IFN when assayed in a system with a lower IFN sensitivity. A simplified model of neutralization reaction was described that provided a theoretical background for this observation. The model also allowed some inferences to be made about the relationship of the titer to the affinity and IFN-binding capacity of the antibody.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6389723     DOI: 10.1089/jir.1984.4.571

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  8 in total

1.  Neutralization of activity of effector protein by monoclonal antibody: formulation of antibody dose-dependence of neutralization for an equilibrium system of antibody, effector, and its cellular receptor.

Authors:  Y Kawade
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

2.  Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.

Authors:  A Ashkenazi; S A Marsters; D J Capon; S M Chamow; I S Figari; D Pennica; D V Goeddel; M A Palladino; D H Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

3.  The nature of neutralization reaction between effector protein and monoclonal antibody: a quantitative study of neutralization characteristics of anti-interferon antibodies.

Authors:  Y Kawade; Y Watanabe
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

4.  Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group.

Authors:  T Niijima
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Quantification of the neutralization of cytokine biological activity by antibody: the ten-fold reduction bioassay of interleukin-6 as growth factor.

Authors:  Sidney E Grossberg; Monika Casey; Leslie D Grossberg
Journal:  J Interferon Cytokine Res       Date:  2009-08       Impact factor: 2.607

6.  The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels.

Authors:  Sidney E Grossberg; Yoshimi Kawade; Leslie D Grossberg
Journal:  J Interferon Cytokine Res       Date:  2009-02       Impact factor: 2.607

7.  Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis.

Authors:  Alexander Y Lau; W K Ip; Cheryl Au; K K Lau; Winnie Wong; K K Yip; Jonas Yeung; S H Li; Patrick Li; Ryan Lee; Deyond Siu; Jill Abrigo; Adrian Wong; Vincent Mok; Eric Chan
Journal:  Mult Scler J Exp Transl Clin       Date:  2017-10-09

8.  Biological and antigenic relationships between virus-induced porcine and human interferons.

Authors:  C La Bonnardière; H Laude; K Berg
Journal:  Ann Inst Pasteur Virol       Date:  2006-09-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.